Female sex hormone-hormone receptor system as a coronary risk factor

女性性激素-激素受体系统作为冠状动脉危险因素

基本信息

  • 批准号:
    13670754
  • 负责人:
  • 金额:
    $ 1.09万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2001
  • 资助国家:
    日本
  • 起止时间:
    2001 至 2003
  • 项目状态:
    已结题

项目摘要

To examine the hypothesis that the abnormality in the estrogen-estrogen receptor system might be the novel coronary risk factor, following studies were performed.<Molecular genetic study>Specific haplotype determined by the combination of two prevalent polymorphisms in estrogen receptor-alpha gene was significant predictor of the onset age of angiographically-confirmed coronary heart disease, and this relation was independent from traditional coronary risk factors (presented at the 66^<th> Annual Scientific Session of Japanese Circulation Society).Another specific haplotype of estrogen receptor-alpha gene was significantly associated with the greater reduction of LDL cholesterol and the greater increase of HDL cholesterol after atorvastatin therapy, which was the most well-established therapeutic choice of atherosclerotic coronary artery disease (in submission).<Circulating sex hormone level>We determined levels of estradiol (E2) using high-sensitive method and free testosterone (FT), … More in 236 consecutive male patients with angiographically-defined stable coronary artery disease and in 143 disease-free and age-matched controls. The levels of high-sensitive E2 and FT in patients and controls differed slightly in opposing directions, but neither difference reached statistical significance. However, the ratio of FT to high-sensitive E2 in patients was significantly higher than in the controls, and this difference remained significant after adjustments for age and body mass index had been made. Multiple regression analysis revealed that age, the association of diabetes, and the presence of coronary atherosclerosis were significantly and independently associated with the values of the FT/high-sensitive E2 ratio. Other hormones examined did not differ significantly between the patients and the controls. High-sensitive E2 measurement demonstrated a significant imbalance of, FT to E2 in male patients with coronary artery disease, but individual sex hormone levels did not differ between the patients and the controls. (in press) Less
为了验证雌激素-雌激素受体系统异常可能是新的冠状动脉危险因素的假设,进行了以下研究。<Molecular genetic study>由雌激素受体α基因中两种流行多态性的组合确定的特定单倍型是血管造影证实的冠心病发病年龄的重要预测因子,并且这种关系独立于传统的冠状动脉危险因素(在日本循环学会第66届年度科学会议上提出)<th>。α基因与阿托伐他汀治疗后LDL胆固醇的更大降低和HDL胆固醇的更大升高显著相关,阿托伐他汀治疗是动脉粥样硬化性冠状动脉疾病最成熟的治疗选择(提交中)。<Circulating sex hormone level>我们用高灵敏度方法测定雌二醇(E2)和游离睾酮(FT)水平, ...更多信息 在236例血管造影确诊的稳定型冠状动脉疾病的连续男性患者和143例无疾病和年龄匹配的对照中。患者和对照组的高敏E2和FT水平在相反的方向略有差异,但差异均未达到统计学显著性。然而,患者的FT与高敏感性E2的比率显著高于对照组,并且在调整年龄和体重指数后,这种差异仍然显著。多元回归分析显示,年龄、糖尿病相关性和冠状动脉粥样硬化的存在与FT/高敏E2比值显着且独立相关。其他激素检查没有显着差异患者和对照组之间。高灵敏度的E2测量显示,在男性冠心病患者中,FT与E2显著失衡,但个体性激素水平在患者和对照组之间没有差异。(in新闻)减

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Kajinami K, et al.: "Imbalance of sex hormone levels in men with coronary heart disease."Coronary Artery Disease. (in press). (2004)
Kajinami K 等人:“患有冠心病的男性性激素水平失衡。”冠状动脉疾病。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TAKEDA Kenji其他文献

TAKEDA Kenji的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TAKEDA Kenji', 18)}}的其他基金

A Comprehensive Research on Kaitokudo
开拓德堂综合研究
  • 批准号:
    25284012
  • 财政年份:
    2013
  • 资助金额:
    $ 1.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Role of Gene33/RALT in oxidative stress-induced signal transduction in cardiac cells.
Gene33/RALT 在心肌细胞氧化应激诱导的信号转导中的作用。
  • 批准号:
    20790557
  • 财政年份:
    2008
  • 资助金额:
    $ 1.09万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
A Study of the Materials Written in the Chu 楚 -Style Characters in the Warring States period
战国楚体文字资料研究
  • 批准号:
    12410004
  • 财政年份:
    2000
  • 资助金额:
    $ 1.09万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)

相似海外基金

Androgen Regulation of CRF Receptor 1 as a mediator of stress responses
雄激素对 CRF 受体 1 的调节作为应激反应的调节剂
  • 批准号:
    10724308
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
Deciphering microbial contribution to androgen bioavailability in castration resistant prostate cancer patients
破译微生物对去势抵抗性前列腺癌患者雄激素生物利用度的贡献
  • 批准号:
    10573918
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
Mechanisms of androgen-dependent Wolffian duct differentiation
雄激素依赖性沃尔夫管分化机制
  • 批准号:
    10633606
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
Project 2: Androgen deprivation as an immune modulating therapy in combination with targeted immunotherapy of prostate cancer
项目2:雄激素剥夺作为免疫调节疗法与前列腺癌靶向免疫疗法相结合
  • 批准号:
    10555401
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
Prostate Specific Anti-androgen Therapy for Localized Prostate Cancer
前列腺特异性抗雄激素疗法治疗局限性前列腺癌
  • 批准号:
    10760194
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
Androgen receptor: A master regulator of lipid metabolism
雄激素受体:脂质代谢的主要调节因子
  • 批准号:
    DP230103210
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
    Discovery Projects
Regulation of androgen receptor signaling in prostate cancer by protein arginine methylation
通过蛋白质精氨酸甲基化调节前列腺癌中的雄激素受体信号传导
  • 批准号:
    10584689
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
Neural and Renal Contributions to Hypertension with Androgen Deprivation Therapy
雄激素剥夺疗法对高血压的神经和肾脏影响
  • 批准号:
    10662133
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
Structural and functional analysis of a novel class of androgen receptor antagonists
一类新型雄激素受体拮抗剂的结构和功能分析
  • 批准号:
    10650956
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
Role of the Androgen Receptor in Insulin Secretion in the Male
雄激素受体在男性胰岛素分泌中的作用
  • 批准号:
    10488954
  • 财政年份:
    2023
  • 资助金额:
    $ 1.09万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了